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Background: Buprenorphine (BNX) is used in Opioid Use Disorder (OUD) deterrence. Optimal 
long-term duration with BNX is unclear, but evidence shows that there is a high risk for relapse 
when medicine is discontinued even if maintenance has been stable for some time. 
Outcomes: The purpose of this project was to decrease barriers for providers implementing BNX 
therapy for individuals diagnosed with OUD. Outcomes measured included: (1) knowledge of 
and barriers to implementing current guidelines, (2) factors preventing use of guidelines, (3) 
recommendations for BNX maintenance as per guidelines.  
Methods: Using a pre-post intervention design, participant knowledge on BNX guidelines, 
factors preventing use and motivation for practice change were measured using non-standardized 
questionnaires. Participants were instructed on current guidelines and recommendations to 
overcome barriers. 
Results: Both providers completed surveys in full. Both providers showed consistency and 
knowledge in the field. DEA limitations with lack of resources and poor treatment models 
contributing to poor guideline adherence was a concern for both providers. One provider 
believed it is beneficial to discontinue BNX at some point while the other encourages more long-
term use. The clinic was pursuing expansion of resources and more providers to alleviate 
barriers. 
Conclusions: Adhering to BNX guidelines have implications on quality of care impacting 
clinical, policy, leadership, and ultimately safety levels placing relapse wellbeing states at risk. 
Results were of value as they discussed important factors necessary to address and ways to 
improve such thus improving outcomes. Greater attention to guidelines and continuous 
advocation is vital for sustainability.
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A Program Development and Evaluation Project for Provider Use of Buprenorphine 
Maintenance 
Since 1999, opiate-related overdose deaths have increased by six-fold on a national scale 
(Centers for Disease Control and Prevention [CDC], 2019). Deaths have also tripled in the state 
of Utah since the dawn of the 21st century surpassing the national rate (National Institute on Drug 
Abuse [NIH], 2019). The term “opidemic” has become a phenomenon indicating the rapid rise in 
use of these substances often leading to addiction and death. Pain was once considered the fifth 
vital sign and various academic institutes nationwide were instructing providers that pain is what 
the patients say it is. Concurrently, opioid prescriptions have reached an all-time high where 130 
Americans die each day from an overdose.  
Therapeutic modalities such as psychotherapy and rehabilitation programs have been 
available to help outcomes for these patients in addition to MAT (medication assisted therapy). 
These medicines are methadone, naltrexone, and BNX. Positive and encouraging outcomes from 
BNX have been shown in published evidence and its usage is expanding. It appears to be 
generally well tolerated and has demonstrated comparable and at times superior benefits to other 
agents. 
 This DNP project consisted of pre-post intervention interviews around BNX guideline 
barriers with provided education. Using the best evidence, recommendations to address barriers 
were developed to transition into practice. An education module was provided on eliminating 
barriers to administering BNX maintenance and management followed by second interviews to 
medical providers assessing if education made a difference in practice. 
Background and Significance 
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In 2017, death rates reached 456 by overdose involving opiates making up 70% of 
overdose-related deaths escalating Utah to above the national average (National Institute on Drug 
Abuse [NIDA], 2019). A near tripling of opioid prescriptions dispensed, and opioid related 
deaths in the United States occurred between 1991 and 2011 (National Institute on Drug Abuse 
[NIH], 2018). Locally, Utah has ranked 7th in the nation for drug poisoning related expirations 
which has outpaced deaths by motor vehicle crashes, firearms, and falls between 2013-2015 
(Utah Department of Health, n.d.). Addiction has frequent relapses with one study reported as 
many as 91% of those in recovery will relapse at one point. In the first week, 59% will use 
substances, and 80% within a month will do so of discharging from detoxing (American 
Addiction Centers, 2019).  
About 2.1 million individuals in this country have a substance use disorder. Misuse of 
prescribed opioids will include 20-30% of individuals, and 10% of those misusing opioids will 
become addicted with 5% trying heroin (Yerby & Hampton, 2019). Unfortunately, the problem 
has escalated to a point where people are losing jobs, families, obtaining criminal records, 
cycling through treatment, and becoming homeless. Many times, an individual goes for a routine 
procedure such as wisdom teeth removal, and short-term opioid treatments become an addiction. 
These people are generally healthy, normal persons with families, careers, and good credit scores 
that fall victim to opioid addictions.    
Opiate misuse is a problem that involves many age groups ranging from early 
adolescence to geriatrics. In 2016, 3.6% of adolescents in this country misused an opioid (Yule, 
Lyons, & Wilens, 2018). Kids aged 12-17 in 2015 requiring substance use treatment reached 1.3 
million (Lipari et al., 2016), and 2.9% of local Utahn teens aged 14-17 had misused prescription 
drugs (Utah Department of Health, n.d.). Between 2009 and 2016 persons aged 55-64 saw rates 
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of overdose deaths rise by 52% while those 65 and over also rose by roughly 20%. Geriatrics 
carry more risk factors as they have higher prevalence of pain compared to younger populations 
(Blow, n.d.).  
Medication Assisted Therapy is a treatment method used in OUD to decrease drug use, 
cravings, criminal activity, and infectious disease transmission while increasing quality of life, 
treatment retention and outcomes (National Institute on Drug Abuse [NIH], 2016). Options 
include Methadone, BNX, and Naltrexone. Methadone is a full opioid agonist, while BNX is a 
partial opioid agonist. Both replace the properties of previous receptor binding from opiate use to 
suppress troublesome symptoms of addiction. Naltrexone is a opioid antagonist blocking 
receptor properties promoting deterrence from opiates and aims to suppress symptoms of 
withdrawal. While it is difficult to make direct comparisons on superiority between the 
medications, methadone and BNX appear to have greater amounts of evidence for success rates 
(Bart, 2012).   
This issue is chronic thus there is no cure. Until recently the concepts of detoxification 
and stand-alone psychological therapy had been the standard for treatment in which relapse rates 
have staggered around an alarming 90% or higher (Velander, 2018). In the 1960s and 70s, trials 
and legal acts such as the Controlled Substances Act of 1970 and Narcotic Addict Treatment Act 
of 1974 helped pave the way for Methadone improving outcomes. However, limitations such as 
restricted access and visiting specialty clinics on daily bases has made it difficult for people to 
receive treatment contributing to relapse rates.  
Buprenorphine was developed in the 1970s fueling the Drug Addiction Treatment Act of 
2000 (Velander, 2018). Due to prevalence and risk among varieties of populations, any 
individual with opiate misuse or carries the diagnosis can potentially benefit from this medicine. 
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Optimal duration of MAT with BNX is unclear, but evidence shows that there is a high risk for 
relapse when MAT is discontinued even if maintenance has been stable for some time (Clinical 
Tools Inc [CTI], n.d., 1 section). 
Needs Assessment 
A SWOT analysis was performed examining the strengths, weaknesses, opportunities, 
and threats of implementation of the project at the project setting (Appendix A). While the 
location for the project had some reservations in terms of longevity and had challenges due to its 
new establishment, it also had its advantages as a location for the DNP project. It was a privately 
owned clinic with a flexible owner, therefore a virtual blank canvas was provided giving the 
freedom to conduct the project as needed. Because substance use is at an all-time high especially 
in the local area, and resources are not as available, the demand is also expected to be high so 
opportunity for a successful project was apparent. With supportive and motivated staff, freedom 
to conduct the DNP project, and baseline funds and resources at disposal, it was expected to be a 
successful endeavor at this location. 
Problem Statement 
 Despite national efforts, the failure and dropout rates of treatment have been high for 
people with OUD as between 4 and 6 people out of ten will relapse upon treatment of OUD 
(National Institute on Drug Abuse [NIH], 2018). Various treatment modalities exist with this 
disorder most often involving a variety of multidisciplinary wrap-around services. These include 
counseling, behavioral intervention, community and group services, long term treatment 
planning, inpatient acute detoxification, and use of medication (American Psychiatric 
Association [APA], 2018). Despite ongoing approaches to treating OUD continual rising rates of 
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opioid-related deaths and overall poor rehab retention continue to occur with notable lack of 
consistencies in treatment. 
An issue in treatment has been consistently suppressing the physical craving needs for 
opioids. Buprenorphine has been available in oral and sublingual forms and has now evolved 
into injectable depot formulations which has shown improved outcomes when compared to 
Methadone and other treatments (Hser et al., 2016). Products containing BNX have shown 
greater outcomes in those with OUD including increased abstinence and treatment retention 
when compared to no medication use (Mokri et al., 2015).  
Current guidelines for BNX management consist of accurate assessment prior to any 
treatment with special considerations of chronic illness or pregnancy. Regimens are to be 
individualized based on opiate usage history and genetic implications. Initiation should not take 
place until 12-48 hours from previous opiate usage to avoid precipitated withdrawal (American 
Society of Addiction Medicine [ASAM], 2015). Optimal duration of maintaining BNX therapy is 
unclear, however there is high risk for opiate relapse when treatment is discontinued (CTI, n.d., 1 
section). However, if circumstances arise for discontinuation such as employment implications 
or patient preference, a slow tapering potentially over multiple months with close monitoring is 
recommended.  
The purpose of this project was to decrease barriers for providers to implement 
buprenorphine (BNX) therapy for individuals diagnosed with opioid use disorder (OUD). 
Aims and Objectives 
The aims of this study were coordinated to direct feedback from providers therefore 
questions were framed to match the needs the study was attempting to answer. The project was 
also attempting to promote change to guideline adherence in BNX maintenance by using 
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evidence, education, and follow up assessments. By assessing knowledge and barriers prior to 
intervention with interviews, baseline data was able to be established for later comparison. 
Immediate follow up feedback after education module provided response data from presentation 
and aims exploring motivation for change. The 6-week follow up assessment helps give insight 
into the long-term impacts made on the providers from the project assessing the retainment of the 
knowledge and obtaining direct feedback on any changes in place or in motion for the future 
pertaining to the intervention. By interview questions with the aims of the study, responses were 
able to meet expectations of the project. 
The objectives included: 
 To explore underlying factors preventing use of guidelines to BNX maintenance within 
the study period. 
 To assess provider knowledge of and barriers to implementing current guidelines. 
 To propose recommendations to clinic providers for practicing standards of care for BNX 
maintenance as published by clinical guidelines. 
 To re-examine knowledge of providers after intervention. 
Review of Literature 
A systematic review was conducted to assess the evidence of BNX in the treatment of 
OUD. CINAHL and PubMed databases were searched. Terms used included “opiate addiction or 
opiate dependence and buprenorphine not methadone not alcohol”, “addiction, opiate and 
buprenorphine”. Number of applicable articles found were 147 following removal of duplicates. 
The articles are appraised using McMaster University’s Quality Assessment Tool for quantitative 
studies. The evidence is summarized in Appendix B. 
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BNX products appeared to be helpful according to the majority of RCTs and quasi-
experimental studies and demonstrated usability in opiate use. Overall abstinence from other 
opioids was improved compared to placebo and other treatment modalities sometimes by a 
significant margin as described by Wang et al (2019). and Haight et al. (2019). Greater 
adherence to treatment with use of BNX compared to naltrexone and placebo showed improved 
rehab potential in these patients with the help of this agent as opposed to psychological based 
therapy alone and/or with pure antagonist treatment. 
 Common barriers in the workforce included insufficient training, experience, and 
education for providers to practice and prescribe BNX for OUD. These included the required 
waiver from the DEA, however majority of physicians in Primary Care and Addiction surveyed 
in New York City cited that earlier, and more reinforced education is needed for successful care 
(Haffajee et al., 2018). There are widespread negative attitudes towards opiate replacement in 
addiction medicine due to its high-risk nature further limiting availability. In addition, there are 
only a certain number of patients the DEA allows at one time to be managed on BNX for 
addiction per provider (Molfenter et al., 2019). Because of these quantity limitations, providers 
may be more likely to be bias towards discontinuing BNX sooner than appropriate.  
 Behavioral health and addiction medicine are often linked and is difficult to find 
substance use patients without a mental health diagnosis. This can be a barrier as many payer 
providers fully endorse mental health support systems such as use of psychotherapy and a 
medication manager for patients to be prescribed BNX. In fact, in Washington State, Medicaid 
will only pay for BNX treatment if the patient also receives substance use counseling 
(Hutchinson et al., 2014). Reimbursement thus can be a challenging barrier while there is better 
coverage than years prior, certain qualifications specifically around Medicaid make it 
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burdensome for some providers (Haffajee et al., 2018). While generic BNX is cheap, the 
BNX/naloxone combination (Suboxone) is often preferred due to its deterrence abilities but can 
be costly.  
Coverage has improved since the Affordable Care Act and Medicaid expansion, but 
continues to be a barrier for those without payer benefits and those with poor insurance plans 
(Molfenter et al., 2019). Like all medicines, BNX has risks of side effects and interactions short 
and long-term. Most common ones include decreased/altered mood and motivation with changes 
in appetite, energy, liver changes, adrenal suppression, headaches, and lightheadedness. Patient 
tolerability varies greatly (Zoorob et al., 2018). 
 Expansion of BNX use and acceptance is a general recommendation among addiction 
professional. This includes more providers, greater resource and care coordination, institutional 
support, adequate training, and decreasing negative perceptions of patients with OUD with or 
without BNX treatment (Haffajee et al., 2018). Ongoing efforts to legislate provider caseload 
expansion granted by the DEA would lessen the burden by increasing availability of services to 
above 270 patients per provider. This and further provider recruitment would greatly benefit the 
barriers to BNX guideline usage (Molfenter et al., 2019).  
Limitations and Gaps in Knowledge 
 With the recent evolution of BNX where it is becoming available in a depot injectable 
form, further time and studies are going to be needed to assess the long-term success and safety 
as opposed to oral agents (Timko et al., 2016). The chemical compositions are different enough 
along with the mode of entry where further examination will be needed to assess its efficacy and 
tolerability. A limitation of oral buprenorphine is the concern of drug diversion (Saloner et al., 
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2017), thus sparking the combination of buprenorphine/naloxone to divert from intravenous use. 
However, because of its agonistic properties, abuse of the agent is still possible.  
A major limitation to the use of BNX includes the policy and DEA-based regulations for 
the use of this agent and its requirements for providers being able to prescribe it for OUD. 
Currently additional training hours are needed to receive the “X” waiver for physicians and mid-
level providers. The first year of practice, only 30 patients can be treated at one time and 100 is 
the limit for the following year (Drug Enforcement Administration [DEA], n.d.). While this 
number increases to 270 by the third year and beyond, these restrictions on treatment numbers 
further binds providers in assisting those with the illness and limiting further progress in the 
national crisis. 
Common limitation themes among appraised evidence included variation and diversity 
among patients/recipients, treatment programs and concurrent treatment regimens such as 
psychotherapy that may impact results as well as sociodemographic factors. Because OUD is 
multifactorial it is often difficult to bottle all aspects of factors into a given report. Another 
theme included some inconsistencies in follow up such as missing data and dropouts with clients. 
Limitations regarding the guidelines of BNX is that there is no clear timeframe on when 
and if to discontinue the use of the medication. The literature more so gives input that many 
patients need to stabilize for many years, and even after doing so the risk of relapse is high when 
discontinued (CTI, n.d.). No concrete numbers exist for optimal doses, nor timeframe leaving 
management open to much interpretation to providers. However, the evidence is clear that poor 
outcomes follow the trend of discontinuation and longer-term use is widely recommended. 
Implications for Practice and Recommendations  
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The literature showed consistency in the effectiveness of BNX in diverse groups of adults 
of multiple ages and ethnicities, as well as multiple forms of BNX formulations including oral 
and injectable forms. BNX is effective when compared to other evidence-based treatments and 
showed similar safety, tolerability, and efficacy (Timko et al.), (Hser et al.), (Feelemyer et al.). 
Given the adequate quality and strength of the evidence, this review supports the translation into 
practice. 
While limitations by the DEA and gray areas in literature exist making generalizability 
difficult, BNX helps lower relapse rates both short and long term (Hser et al., 2016). SAMSA 
(2016) has declared that discontinuing BNX is not required, and that therapy can continue 
indefinitely if there are no complications, and they adhere to protocols. The VA/DOD guidelines 
recommend providers to strongly advise patients to continue BNX maintenance long-term due to 
the failure rates when discontinuing (Department of Veterans Affairs, & Department of Defense, 
2015). There are appropriate times for discontinuation of treatment which include 
hypersensitivity, adverse reactions, and mishandling of the medicine. 
  As with all other areas of medicine, patient preferences, availability, and provider 
experience and their comfort are factors to consider when prescribing treatment which is why 
having treatment options is important. When it comes to treating those with OUD and as per best 
evidence, BNX should be considered. Its short- and long-term efficacy data combined with its 
tolerability and safety profiles give clear indicators that it can help improve quality of life. 
Methods 
Interviews were conducted in a pre- and post-intervention design to gather data. Two 
medical providers practicing in outpatient addictionology participated in the study. Pre 
intervention aims were to explore current evidence-based guidelines of BNX maintenance, and 
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to assess provider knowledge of and barriers to implementing current guidelines. Responses 
were recorded and inputted into software for later analysis. This data then was compared to 
literature on best practice and barriers to follow recommended guidelines. Post-intervention aim 
was to assess provider thoughts on education of BNX guidelines and motivation for any change 
in practice. Information was collected by same means of surveying providers via interviews. 
Analyses were made in reflection to intervention as well as prior knowledge to look at impacts 
made from education. The final outcome measured 6 weeks following intervention was to re-
examine knowledge of providers and assess any movement in practice changes. This data gives 
further insight into motivation, retainment of education and impacts pertaining to BNX 
guidelines and barriers translating into practice. 
Excel was the software used to store and analyze data. Providers were given a non-
identifiable number along with their role and years in addictionology practice. Responses to 
interview questions were directly inputted into the spreadsheet and placed side-by-side for 
comparison. To ensure accuracy of entry, initial data was transcribed by hand onto paper during 
interview process. Each provider had their own paper with questions and answers written out to 
ensure correct obtainment, as well as their names written at the top to differentiate. Data was 
then transferred to the Excel spreadsheet under the respected provider rows with paper copies 
kept to backup information. Data was double checked for accuracy by providers giving 
responses. All data was entered by project lead, care was taken to keep all data confidential and 
non-identifying. No significant outliers were noted. 
There were no standard instruments available unique to this pilot project, therefore new 
ones were created to meet the needs consisting of pre- and post- questionnaire surveys. The pre-
questionnaire survey collected demographic information of the participants including education, 
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race, sex, and years in practice. It was designed to gather baseline data information of the 
provider’s knowledge of current guidelines of BNX management in OUD, and their attitudes and 
opinions on factors preventing the guidelines being followed properly in practice. PowerPoint 
software was utilized in creating the educational module the project lead presented to the 
providers while giving resources and data supporting evidence to information. The post-survey 
assessed provider attitudes and feelings and most importantly motivation toward any potential 
change in practice after the educational session. Finally, a 6-week follow up survey included 
assessment of any changes in the practice or upcoming means in reflection to the project’s 
impacts. Due to the originality of the tools to this project, validity, and reliability could not be 
properly determined and is recognized as a weakness to the project. 
Participants and Recruitment 
Both clinic providers were certified in treating addiction medicine and been doing so 
since the opening of the clinic. They ran the BNX management of the clinic and had full control 
of the operations with any changes as they felt appropriate. Both participants were recruited via 
direct approach by the project lead. 
Consent Procedure and Risks/Harms 
 George Washington University IRB was consulted, and as this was a QI pilot program 
involving addictionology providers and minimal risk to participants, the project was deemed IRB 
exempt. No patient data was collected. Participation was fully voluntary, and withdrawal could 
occur at any time without consequence. Study was minimal risk, and consent was implied when 
participants became involved in the intervention. See Appendix F for implied consent form. Both 
providers were individually asked for willingness to participate in the project with full disclosure 
of its contents with benefits around the continuing education of their specialized field, and 
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resources, and increased interdisciplinary collaboration in their clinic and community. Risk to the 
participant was potential peer pressure to participate and potential psychological distress when 
dealing with mental health and addiction concerns of patients. There was some degree of bias in 
this project as participants may have known the project lead. Additionally, because this study 
was not blinded, participants were aware of the purpose and may have unintentionally been 
swayed to respond favorably to the intervention. It was emphasized that honest responses on the 
multiphasic surveys were expected with participation. 
Costs and Compensation 
 No additional resources were in need for tasks and interventions for this project. 
Educational materials were all electronic with surveys done orally. Because the clinic was 
equipped with computer software, data management systems was able to be utilized via provided 
equipment by the clinic as well free of charge. Compensation was not provided. 
Project Interventions 
Initially, providers were interviewed assessing knowledge of current clinical practice 
guidelines for BNX maintenance and factors contributing to barriers for implementation. They 
were asked to provide their policies and procedures of the clinic when it comes to BNX therapy. 
The purpose of the initial interview was to determine baseline knowledge and their perception of 
barriers for later comparison, analysis, and recommendations. 
Education was provided via an educational module. PowerPoint slides discussed 
surveyed topics in detail with national and state level implications. Traditional lecture style with 
interaction to engage and encourage participation helped intervention remain relevant and 
interesting for participants. Estimated time needed was roughly 45 minutes. 
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Post-intervention interviews analyzed provider views on updated practice guidelines 
while addressing previously mentioned barriers. These sessions assessed impacts from the 
education sessions and any potential changes to the clinic in the future for practice. 
Outcomes Measured 
 Outcomes to be explored included knowledge and barriers from the feedback given by 
the medical providers around the educational session on BNX maintenance guidelines. Initial 
interviews gave their baseline knowledge and barriers to implementing guidelines. Following the 
educational sessions, re-interviewing providers seeing if education made a difference on 
elimination of barriers and views of management was documented. After six weeks, final 
interviews took place regarding the recommendations of guidelines assessing any differences 
made in practice and elimination of barriers. Survey processes measured the knowledge and 
barriers for data collection.   
Timeline and Resources 
 The projected timeframe for this initiative was 6 weeks of field work in total. The 
justification for this timeframe was to assess the impacts and changes in practice following the 
educational session, and data management. Assessment and education took place on week 1 with 
outcomes interview on week 6. See Appendix C depicting on-site timeline.  
Several resources for the project were already in place. These included working staff, 
software systems, and office infrastructure. Other working office hardware and computer 
programs were available for creation, management, and implementation of education materials. 
Ensuring of a working data application was a necessity upon initiation to ensure confidentiality, 
reliability, and consistency. 
Evaluation Plan 
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 The premise of evaluation was to analyze the data as they related to the goals and 
outcomes. The data collection process was ongoing and conducted by the student DNP. Pertinent 
data came from the interview processes and direct responses from the providers. Data were 
collected via handwritten responses and transcribed by the project lead into Microsoft Excel. 
Data resided on an excel spreadsheet saved to a firewall and virus-protected computer which was 
password protected leaving access to only the project lead. Data was deidentified giving 
participants codes instead of personalized information prior to examination and publication. To 
ensure all necessary data made it to the software from handwritten notes, organized and 
individual pieces of documentation were done separately for each provider per interview session 
lessening risk of missing data.  
Data Analysis, Maintenance & Security 
 For data analysis, responses were listed for each provider in summaries in pre- and post- 
intervention columns – as well as a 6-week post intervention survey column. Common themes 
were explored and compared to best evidence. Finally, feedback from providers on their changes 
of practice pertaining to guidelines were inputted assessing impacts from the project.  
 No formal assistance in data analyses and sorting processes were used as they were all 
performed by the student project lead. Formal plan for sorting pertinent data, coding for common 
quality improvement themes, and plans for processing for specific key points were in place 
ahead of time. 
 Maintaining and securing pertinent data was trusted via software and firewall systems. 
Spreadsheet software was utilized in creating data visuals depicting transcribed nominal, 
interval, ordinal, and ratio data. Regular viral scans and security checks were done to ensure no 
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security threats in addition to email monitoring for potential harms. IT support systems were in 
place for as needed software troubles. 
Results 
Of the two targeted participants, both fully completed the project in its entirety with no 
dropouts or missing data. One was a male Physician certified in Addictionology with 8 years’ 
experience using BNX therapy, and whom of which was the owner of the clinic. He had original 
certifications in general medicine and practiced for 15 years in long-term care settings before 
obtaining secondary certifications in addiction medicine where he has managed detox and 
maintenance programs on inpatient and outpatient levels of care. Second, was a female APRN 
with greater than 5 years’ experience in the field starting as an RN working inpatient with OUD 
patients and eventually becoming a prescriber in the clinic doing so now for 2 years. Most of her 
nursing background consisted of both addiction medicine and mental health care doing inpatient 
detox and maintenance while obtaining her master’s degree and transitioning to an APRN. They 
varied on education levels, certifications, and experience, however, shared similar histories in 
practicing in mental health and addictionology whether it be nursing or provider levels in 
multiple counties serving different types of patients. 
 Pertaining to the guidelines both providers appeared to be well-versed in today’s 
recommendations and they agreed on multiple aspects. Pertaining to the safety of the drug, both 
providers agreed that people can use the medicine long term for opioid deterrence and without 
the help of pharmacotherapy people are at risk for relapse. Like any medicine it has its risks and 
side effects, and the ratio of risk vs benefit needs to be weighed for each patient. Both providers 
said that BNX helps outcomes and multiple aspects impacts outcomes.  
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The DEA plays a vast role in limiting the number of patients managed on BNX per 
provider for maintenance (i.e., 275 at one time). A common barrier in guideline adherence is that 
opiate use is viewed as a behavioral issue and not a medical based condition impacting stigma 
leading to less resources, difficult reimbursement, and lesser compliance from patients.  
While both providers agreed BNX is safe most of the time, they differed on long-term 
opinions. The Physician (Provider101) believed that people can benefit from eventually coming 
off the medicine as it can increase their overall cognitive abilities and generalized function 
despite the risk of relapse. He also discussed the lack of medical providers and resources impact 
guideline adherence and interferes with maintenance. The APRN (Provider102) differed 
believing that if BNX is helping a patient stay sober then they should be taking the medicine as 
long as possible unless there is a good reason to come off and great caution should be used. 
Provider102 went on to say each patient is individualized in their care and will make their own 
decisions, but risks of discontinuing should be fully advised. She also discussed that BNX in its 
Brand form Suboxone can be expensive without payer coverage which can impact one’s 
compliance to treatment. 
Both participants in the post survey were wanting to expand the clinic in hopes of better 
overall patient care with BNX therapy. They agreed that greater resources, hiring more providers 
and continued use of the medical model can help the problem. At 6-week follow-up the clinic 
was in the process of finalizing agreements with several insurance carriers and hiring more help. 
Both were motivated to providing optimal care and keeping people sober. Provider101 still 
believed there were benefits to coming off BNX if possible, however if they choose to come off 
and relapse, they can be put back on BNX maintenance right away. Provider102 still encouraged 
patients to remain on treatment if the benefits were present and if the desire to come off was 
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there then close follow up needed to occur. Provider101 then proceeded to offer the project lead 
a working provider position at the clinic. See Appendix F, Table 5 for complete data analysis. 
Analysis of Aims/Objectives 
To evaluate Objective 1: explore underlying factors preventing use of guidelines to BNX 
maintenance. Survey questions were asked to providers pertaining to the lack of adherence to 
established evidence done often in practice and what contributions exist. Feedback established 
baseline data to the providers knowledge and opinions for later comparison in post-intervention 
surveys. Many similarities between the two providers exist including lack of resources, federal 
limitations, and reimbursement issues. However, there are differing opinions on timelines with 
usage of BNX among the two due to potential side effects.   
To evaluate Objective 2: assess provider knowledge of and barriers to implementing 
current guidelines, pre-survey interviews conducted consisted of questions assessing evidence-
based practice for BNX and further exploration deviating from these guidelines. Answers and 
data indicated responses from reliable, professional sources with respected experiences and 
opinions of which are up to date on current evidence and problems in the field. Further baseline 
data provided for later comparison. 
To evaluate Objective 3: propose recommendations to clinic providers for practicing 
standards of care for BNX maintenance as published by clinical guidelines, a slideshow 
educational presentation was given to both providers showing best evidence on BNX 
management and guidelines for practice. The resources used indicated that while there no clear 
objective instructions on BNX therapy, guidelines exist that have determined best care and 
greater outcomes. 
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Finally, to evaluate Objective 4: re-examine knowledge of providers after intervention, 
questions assessing motivation for any change in practice immediately following presentation as 
well as 6 weeks later were asked. This data indicated knowledge adherence, and motivation for 
change in accordance with best practice. Both providers depicted passion for the field, wanting to 
expand their practice in hiring more providers believing that getting more help is the key to 
breaking through some key barriers to BNX guideline adherence and expanding coverage. While 
some differences still exist in the belief of if/when to discontinue BNX, both believe these 
patients are to be managed very closely and safely while always striving to keep sobriety. 
Discussion 
 This project served as a powerful tool for practice emphasizing that OUD treatment and 
BNX maintenance struggle to adhere with what the guidelines recommend. Clinically, the needs 
for BNX therapy are high and are projected to stay that way therefore the demand for quality 
care is going to maintain. While each patient is unique and deserves individualized care, 
generally the more the guidelines are shied away from, the less optimal the outcomes will be. For 
example, poor practice resources and support coupled with too great of demand of patients leads 
to medical provider burnout causing them to resign from practice therefore leading to patients 
coming off BNX for non-personal reasons.  
While the success rates for BNX have been encouraging when regimens are complied 
with, barriers will be ongoing challenges in the form of finances, resources, compliance, and 
longevity. The decision whether to come off BNX will vary on the patient and the provider, and 
while the evidence is clear that relapse rates escalate when off the medicine, there is argument 
that other potential improvements can be seen with discontinuation and they are worth the risk. 
This variation in opinion can impact sobriety rates and place more patients at risk, and when this 
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situation comes in practice a full safety plan is vital to the patient’s chances of success including 
if they can re-initiate BNX upon relapse. 
A focal point in health policy pertaining to BNX therapy is the DEA waiver and 
limitations set on providers. The expansion of such has allowed APRNs and PAs to now 
prescribe BNX which has benefitted more individuals in keeping sober, however capping loads 
at 275 at one time is inhibitory – and that load is only achievable at year three. Other controlled 
substances schedule 2-5 do not have limitations similar to BNX for OUD, and this limitation 
further restricts accessibility and optimal guideline adherence for medicine usage. Furthermore, 
the varying degrees of reimbursement and payor plan coverages threaten ongoing outcomes 
whether it be financing limited amounts of OUD treatment or restricting altogether. These types 
of policies largely impact optimal adherence to guidelines by patients and providers and can 
contribute to poor patient outcomes including relapse. 
Executive leadership can help lessen the barriers for BNX guidelines by helping ensure 
proper resources are in place for practices and providers. Optimal communication and 
agreements with insurance carriers and financial plans are vital for thriving of the practice, while 
also consideration for those patients less fortunate. Whether it be having a pro bono funding 
program or contracting with fellow practices can help bridge the reimbursement challenges while 
avoiding going against BNX treatment guidelines and patient treatment.  
Leadership in practice must ensure enough medical providers given the DEA limitations 
and in consideration of natural provider burnout. Changing the stigma of OUD from a behavioral 
based problem to a medical issue can help anchor greater success rates and gather more 
attraction from patients, the community, resources, and payor plans. The more consistency 
attracted to treatment regimens means greater guideline adherence and outcomes. Ongoing 
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advocation for legislative and financial support on the state and federal levels along with further 
general resources would help nurture the addictionology staff as well as increase generalized 
urgency on the problem. 
Guidelines for BNX like majority of others were created for best quality use of care and 
patient safety. When barriers are seen in practice, safety risks such as patient sobriety and 
revolving circumstances including psychosocial, financial, and legal consequences are at stake. 
Inconsistent use of guidelines can also lead to patient hospitalizations for withdrawal or medical 
decompensations related to opiate use, such as vascular and skin infections related to intravenous 
opiate use. 
Lessening barriers will assist in consistency in patient care in BNX therapy thus bettering 
overall quality. Addiction is extremely difficult for an individual to overcome by itself without 
barriers in treatment. To optimize quality of care, patients need to be fully informed of the 
medication specifically risk of discontinuation despite opinions of provider. Possible benefits are 
pertinent to discuss as well in addition to strong safety plans if the subject were to approach to 
help overcome barriers and improve outcomes. 
Plans for Sustainability and Future Scholarship 
 As demonstrated by the individuals that participated in this study, ongoing expansion and 
advocation of such is pertinent for complying with guidelines to BNX and maintaining good 
outcomes. By optimizing reimbursement opportunities with private and federal insurance 
carriers, further expansion of resources such as more providers and case workers can then in turn 
attract more business. Designated personnel for each practice need to maintain relationships with 
payor plans while enforcing requirements made for reimbursement. 
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 Providers and medical staff need to be fully informed of guidelines for BNX management 
and will need to maintain continuing education requirements demonstrating ongoing 
competence. Setting standard schedules for patient follow up visits with or without being on 
BNX with adjustments accordingly promotes consistency in treatment. Strong treatment plans 
with ample education components help to lessen non-compliance thus interrupting care. By 
creating optimal care plans and performing high quality, evidence-based care, business in turn 
improves thus strengthening the ability to obtain more resources furthering helping comply with 
guidelines. 
Conclusion 
Opiate use disorder is a largely prevalent problem nationally and locally in the state of 
Utah. Relapse and failure rates are high, resource availability is low, and the great need for 
treatment resources is growing by the year. This project focused on provider identification of 
barriers to treatment of adults with OUD in an outpatient clinic, the barriers in implementation of 
established guidelines showing high relapse rates when discontinuing BNX, and education in 
overcoming such.  
While there are multiple barriers to following all elements to BNX guidelines, changes 
can be made to help adherence bettering outcomes for patients. DEA limitations, reimbursement 
challenges, and poor general resources are ongoing challenges and strong advocation is 
important. Greater investment in multidisciplinary approaches and medical providers while 
consciousness of best evidence in treatment can help with outcomes in sobriety. Individualized 
care and preferences continue with respect to patient choice, however strong encouragement in 
supportive discussion has shown to help compliance rates in BNX therapy thus lowering relapse 
rates, hospitalizations, and bettering outcomes.  
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Adhering to guidelines play important roles in patient safety in clinical practice 
infrastructure, contributions from health policy, advocation needed from leadership, and are key 
to best-evidence quality care. The value of these results reinforces the importance and urgency of 
attention needed to addictionology, particularly OUD, given the large increase in usage with 
expected needs continuing to rise. These recommendations can assist in the great impact of the 
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 Favorable treatment models 
 Support from stakeholders 
 Need for substance use treatment 
 Open-minded, patient oriented practice 
Threats 
 External competition 
 Payer sources 
 Vulnerable population 
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Table 4: Data Dictionary 
Data Element Data Label Data Type Definition/Purpose 
 






Unique identifier Alpha-numeric 
Gender gender Numeric, 
continuous 
Age in years 1, Male; 2, 
Female; 3, 
Transgender; 
4, Other; 5, 
Prefer Not to 
Disclose 




















Years practiced years Numeric, 
continuous 
Number of years 
worked with 







know_guide Text What is your 
knowledge of 
current published 
guidelines for BNX 
maintenance 









fact_prevent Text What are factors 
and barriers 













prov_motiv Text What is your 
feedback and 














post_change Text What are your 
thoughts on our 
previous session 

























Informed Consent for Participation in a Research Study 
 
Title of Study: A Program Development and Evaluation Project for Provider Use of 
Buprenorphine Maintenance 
IRB #: N/A 
Principal Investigator Name: Kyle Olson, APRN 
Version Date: 4/4/2021 
 
You are invited to participate in a research study under the direction of Kyle Olson, 
APRN of the Department of Nursing George Washington University (GWU). Taking part 
in this research is entirely voluntary, and you may decide to withdraw from the study at 
any time.  Further information regarding this study may be obtained by contacting Kyle, 
the principal investigator at telephone number 801-201-8001.  
 
The purpose of this study is to decrease barriers for providers implementing 
buprenorphine therapy for individuals diagnosed with opioid use disorder. 
 
What are the reasons you might choose to volunteer for this study? Continuing 
education of their specialized field, and resources, and increased interdisciplinary 
collaboration in their clinic and community. 
 
What are the reasons you might not choose to volunteer for this study? Potential 
peer pressure to participate and potential psychological distress when dealing with 
mental health and addiction concerns of patients. 
 
If you choose to take part in this study, you will be presented an educational module 
with pre- and post- intervention surveys as well as a 6-week follow up survey. The total 
amount of time you will spend in connection with this study is 90 minutes. You may 
refuse to answer any of the questions and you may stop your participation in this study 
at any time.    
 
Possible risks or discomforts you could experience during this study include: loss of 
confidentiality or psychological stress. 
 
You will not benefit directly from your participation in the study. The benefits to science 
and humankind that might result from this study are: Spread awareness to the barriers 
of opioid addiction treatment and recommendations to improve outcomes. 
 
Every effort will be made to keep your information confidential, however, this can not be 
guaranteed. You will be given non-identifiable numbers in data collection and 
interviewed independently. If results of this research study are reported in journals or at 




The Office of Human Research of George Washington University, at telephone number 
(202) 994-2715, can provide further information about your rights as a research 
participant.  
 
To ensure anonymity your signature is not required, unless you prefer to sign it.  
  
Your willingness to participate in this research study is implied if you proceed.  












Table 5: Data Analysis 
 
